Fig. 4.
Fig. 4. Effect of Deltaext-myc on monocyte survival. / Ten thousand monocytes were cultured for 6 days with 10% FCS IMDM with 10 ng/mL of M-CSF. In panel A, the effect of immobilized and nonimmobilized ligand was compared by adding the soluble Deltaext-myc (0, 0.3, 1, 3, and 10 μg/mL) to plastic wells that were previously coated (●) or not coated (○) with 10 μg/mL of 9E10 F(ab′)2 anti-myc antibody fragments. In panel B, controls consisting of purified control medium from noninfected NSO cells and control antibody fragments are shown. Monocytes (5 × 103) were cultured with M-CSF in the presence of 1 μg/mL of Deltaext-myc or control medium in wells coated with 9E10 F(ab′)2 or anti-CD20 F(ab′)2 antibody fragments. (*) represents statistical differences between cultures containing Deltaext-myc in the presence of 9E10 F(ab′)2 antibody fragments and either cultures containing control medium in the presence of 9E10 F(ab′)2 antibody fragments or cultures containing Deltaext-myc in the presence of control, anti-CD20 F(ab′)2 antibody fragments.

Effect of Deltaext-myc on monocyte survival.

Ten thousand monocytes were cultured for 6 days with 10% FCS IMDM with 10 ng/mL of M-CSF. In panel A, the effect of immobilized and nonimmobilized ligand was compared by adding the soluble Deltaext-myc (0, 0.3, 1, 3, and 10 μg/mL) to plastic wells that were previously coated (●) or not coated (○) with 10 μg/mL of 9E10 F(ab′)2 anti-myc antibody fragments. In panel B, controls consisting of purified control medium from noninfected NSO cells and control antibody fragments are shown. Monocytes (5 × 103) were cultured with M-CSF in the presence of 1 μg/mL of Deltaext-myc or control medium in wells coated with 9E10 F(ab′)2 or anti-CD20 F(ab′)2 antibody fragments. (*) represents statistical differences between cultures containing Deltaext-myc in the presence of 9E10 F(ab′)2 antibody fragments and either cultures containing control medium in the presence of 9E10 F(ab′)2 antibody fragments or cultures containing Deltaext-myc in the presence of control, anti-CD20 F(ab′)2 antibody fragments.

Close Modal

or Create an Account

Close Modal
Close Modal